Corvas Restructures Management Team.

SAN DIEGO--(BUSINESS WIRE)--July 9, 1996--Corvas International, Inc. (NNM NNM Network Node Manager
NNM NASDAQ National Market (financial)
NNM National Nutrition Month (March; American Dietetic Association)
NNM Naryan-Mar (Russia)
NNM Net New Money :CVAS CVAS Controlled Vehicle Access System
CVAS Configuration Verification Accounting System (NASA) ) announced today that chief operating officer Chief Operating Officer (COO)

The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. and executive vice president, Donald H. Picker, Ph.D. has left the company. For now, the remaining vice presidents will report directly to the newly appointed chief executive officer, Randall E. Woods.

Corvas International, Inc. is a biopharmaceutical company engaged in the design and development of a new generation of therapeutic agents for the prevention and treatment of major cardiovascular and inflammatory diseases. Corvas is currently collaborating with Schering-Plough Corp. in the development of oral thrombin inhibitors for chronic cardiovascular disease, with Pfizer Inc. to develop neutrophil neutrophil /neu·tro·phil/ (noo´tro-fil)
1. a granular leukocyte having a nucleus with three to five lobes connected by threads of chromatin, and cytoplasm containing very fine granules; cf. heterophil.

2. inhibitory factor (NIF NIF

See: Note issuance facility ) as a possible stroke therapy, and has product licensing agreements with Ortho Diagnostic Systems Inc. (a Johnson & Johnson company) and Centocor Inc. -0-

Note to Editors: For background information on Corvas' technology and product development programs, please contact Angela Hartley, Director, Investor Relations, at Corvas, at 619/455-9800. For information on Corvas International, Inc. via facsimile at no cost, call 1-800-PRO-INFO and enter ticker symbol CVAS.

CONTACT: John E. Crawford, 619/455-9800

Angela Hartley, 619/455-9800

angela_hartley@corvas.com

COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.

Reader Opinion

Article Details
Printer friendly Cite/link Email Feedback
Publication:	Business Wire
Date:	Jul 9, 1996
Words:	187
Previous Article:	CONNECT! Quick improves performance of Java applets, now available for free download.
Next Article:	Community Medical Transport signs definitive agreement to acquire PE Medical Transport of New Jersey.
Topics:	Biological products Biotechnology industries Officials and employees Biotechnology industry Officials and employees Drugs Immunotherapy Pharmaceutical industry Officials and employees

Related Articles
Corvas reports fourth quarter and year-end results.
Corvas announces settlement of shareholder suit.
Corvas announces extension of Schering-Plough option.
Corvas appoints Picker as executive vice president and chief operating officer.
The worm turns - into a source of new drugs.
Corvas reports progress in antithrombotic drug programs; clinical supply manufacturing contract also announced.
Genetronics elects Denison and Nash to board.
Corvas appoints Randall E. Woods as president and chief executive officer.
SCHOOL BOARD BACKS ZACARIAS' OVERHAUL PLAN.
Restructuring recommendations.